论文部分内容阅读
目的:评价青光眼治疗药物醋甲唑胺用于2型糖尿病治疗的有效性及安全性。方法:选择我院2型糖尿病初诊患者64例,随机分为两组,其中醋甲唑胺治疗组32例,对照药物二甲双胍32例。观察并比较两组患者治疗前后血糖及糖化血红蛋白水平变化,以及肝肾功能、血尿常规等安全性指标。结果:与治疗前比较,两组患者治疗后糖化血红蛋白水平均下降,差异具有统计学意义(P<0.05);但治疗后两组间糖化血红蛋白水平比较,差异无统计学意义(P>0.05);两组治疗前后肝功肾功等生化指标之间比较,差异无统计学意义(P>0.05);两组用药安全性比较,差异无统计学意义(P>0.05)。结论:醋甲唑胺与二甲双胍具有相似的降血糖疗效,可作为新的治疗糖尿病的二线药物选择性使用。
Objective: To evaluate the efficacy and safety of glaucoma treatment with methazolamide in the treatment of type 2 diabetes mellitus. Methods: Sixty-four newly diagnosed type 2 diabetic patients in our hospital were randomly divided into two groups, including 32 cases in the metforzamide group and 32 cases in the control group. Observe and compare the changes of blood glucose and HbA1c before and after treatment, as well as the safety indexes such as liver and kidney function, hematuria routine and so on. Results: Compared with those before treatment, the levels of HbA1c in both groups decreased after treatment, with statistical significance (P <0.05). However, there was no significant difference in HbA1c between the two groups after treatment (P> 0.05) There was no significant difference between the two groups in biochemical indexes such as liver function and kidney function before and after treatment (P> 0.05). There was no significant difference in safety between the two groups (P> 0.05). Conclusion: Methazoline and metformin have similar hypoglycemic effects and can be used as second-line drugs for the new treatment of diabetes.